Skip to main content
Top
Published in: Pituitary 3/2009

01-09-2009 | Case Report

Cushing’s syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma

Authors: R. A. Alwani, S. J. C. M. M. Neggers, M. van der Klift, M. G. A. Baggen, G. J. L. H. van Leenders, M. O. van Aken, A. J. van der Lely, W. W. de Herder, R. A. Feelders

Published in: Pituitary | Issue 3/2009

Login to get access

Abstract

Ectopic adrenocorticotropin (ACTH) secretion accounts for less than 10% of all causes of endogenous Cushing’s syndrome (CS) and is usually associated with neuroendocrine tumors and small cell carcinoma of the lung. We report the case of a 62-year-old man with CS due to ectopic ACTH production by small cell carcinoma of the prostate. He presented with severe hypercortisolism and associated symptoms. Plasma neuron specific enolase (NSE) was grossly elevated. Despite performing a laparoscopic bilateral adrenalectomy, the patient died as a result of sepsis with multi-organ failure. Post-mortem immunohistochemical staining of prostate tumor tissue showed ACTH expression. ACTH staining was also performed in four additional patients with small cell carcinoma of the urinary tract without CS. None of these additional cases showed a positive staining for ACTH. Although a rare cause of ectopic ACTH production, neuroendocrine prostate carcinoma should be considered in male patients with Cushing’s syndrome, in particular in those with an occult source of ACTH overproduction.
Literature
1.
go back to reference Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK (2005) Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab 90:4955–4962 Medline. doi:10.1210/jc.2004–2527 PubMedCrossRef Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK (2005) Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab 90:4955–4962 Medline. doi:10.​1210/​jc.​2004–2527 PubMedCrossRef
3.
go back to reference Isidori a M. Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, Jenkins PJ, Monson JP, Grossman a B, Besser GM (2006) The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 91:371–377 Medline. doi:10.1210/jc.2005-1542 CrossRef Isidori a M. Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, Jenkins PJ, Monson JP, Grossman a B, Besser GM (2006) The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 91:371–377 Medline. doi:10.​1210/​jc.​2005-1542 CrossRef
4.
6.
go back to reference Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52:23–47 Medline. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52:23–47 Medline.
9.
go back to reference Di Sant’agnese PA (1995) Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer (Suppl) 75:1850–1859 Di Sant’agnese PA (1995) Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer (Suppl) 75:1850–1859
10.
go back to reference Mosca A, Berruti A, Russo L, Torta M, Dogliotti L (2005) The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 28:141–145 Medline Mosca A, Berruti A, Russo L, Torta M, Dogliotti L (2005) The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 28:141–145 Medline
11.
12.
14.
go back to reference Fjellestad-Paulsen A, Abrahamsson PA, Bjartell A et al (1988) Carcinoma of the prostate with Cushing’s syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue. Acta Endocrinol (Copenh) 119:506–516 Medline Fjellestad-Paulsen A, Abrahamsson PA, Bjartell A et al (1988) Carcinoma of the prostate with Cushing’s syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue. Acta Endocrinol (Copenh) 119:506–516 Medline
15.
16.
go back to reference Hussein WI, Kowalyk S, Hoogwerf BJ (2002) Ectopic adrenocorticotropic hormone syndrome caused by metastatic carcinoma of the prostate: therapeutic response to ketoconazole. Endocr Pract 8:381–384 Medline Hussein WI, Kowalyk S, Hoogwerf BJ (2002) Ectopic adrenocorticotropic hormone syndrome caused by metastatic carcinoma of the prostate: therapeutic response to ketoconazole. Endocr Pract 8:381–384 Medline
19.
go back to reference Rickman T, Garmany R, Doherty T, Benson D, Okusa MD (2001) Hypokalemia, metabolic alkalosis, and hypertension: Cushing’s syndrome in a patient with metastatic prostate adenocarcinoma. Am J Kidney Dis 37:838–846 Medline Rickman T, Garmany R, Doherty T, Benson D, Okusa MD (2001) Hypokalemia, metabolic alkalosis, and hypertension: Cushing’s syndrome in a patient with metastatic prostate adenocarcinoma. Am J Kidney Dis 37:838–846 Medline
21.
go back to reference Francia G, Davi MV, Montresor E, Colato C, Ferdeghini M, Lo Cascio V (2006) Long-term quiescence of ectopic Cushing’s syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine? J Endocrinol Invest 29:358–362 MedlinePubMed Francia G, Davi MV, Montresor E, Colato C, Ferdeghini M, Lo Cascio V (2006) Long-term quiescence of ectopic Cushing’s syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine? J Endocrinol Invest 29:358–362 MedlinePubMed
22.
go back to reference Chu JW, Matthias DF, Belanoff J, Schatzberg A. Hoffman a R, Feldman D (2001) Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86:3568–3573 Medline. doi:10.1210/jc.86.8.3568 PubMedCrossRef Chu JW, Matthias DF, Belanoff J, Schatzberg A. Hoffman a R, Feldman D (2001) Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86:3568–3573 Medline. doi:10.​1210/​jc.​86.​8.​3568 PubMedCrossRef
23.
go back to reference Nieman LK, Chrousos GP, Kellner C et al (1985) Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536–540 MedlinePubMedCrossRef Nieman LK, Chrousos GP, Kellner C et al (1985) Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536–540 MedlinePubMedCrossRef
26.
go back to reference Stewart PM, Gibson S, Crosby SR et al (1994) ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol (Oxf) 40:199–204 MedlineCrossRef Stewart PM, Gibson S, Crosby SR et al (1994) ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol (Oxf) 40:199–204 MedlineCrossRef
28.
go back to reference Delisle L, Boyer MJ, Warr D et al (1993) Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications Arch Intern Med 153:746–752 Medline. doi:10.1001/archinte.153.6.746 Delisle L, Boyer MJ, Warr D et al (1993) Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications Arch Intern Med 153:746–752 Medline. doi:10.​1001/​archinte.​153.​6.​746
29.
go back to reference Gewirtz G, Yalow RS (1974) Ectopic ACTH production in carcinoma of the lung. J Clin Invest 53:1022–1032 MedlinePubMedCrossRef Gewirtz G, Yalow RS (1974) Ectopic ACTH production in carcinoma of the lung. J Clin Invest 53:1022–1032 MedlinePubMedCrossRef
Metadata
Title
Cushing’s syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma
Authors
R. A. Alwani
S. J. C. M. M. Neggers
M. van der Klift
M. G. A. Baggen
G. J. L. H. van Leenders
M. O. van Aken
A. J. van der Lely
W. W. de Herder
R. A. Feelders
Publication date
01-09-2009
Publisher
Springer US
Published in
Pituitary / Issue 3/2009
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-008-0100-z

Other articles of this Issue 3/2009

Pituitary 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine